MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
VANCOUVER, British Columbia, June 13, 2017 -- AbCellera Biologics, Inc. announced today a new therapeutic antibody discovery collaboration with Teva Pharmaceutical Industries, Ltd. Under the agreement, which builds on a successful first partnership completed in 2016, AbCellera will apply its proprietary monoclonal antibody (mAb) screening platform for the discovery of antibodies that modulate the function of an undisclosed membrane protein target elected by Teva.
Carl Hansen, founding CEO of AbCellera, commented: “We are excited to expand our relationship with the innovative team at Teva. This follow-on project marks an important step in establishing AbCellera's platform as an enabling technology for difficult target classes that have proven intractable by conventional antibody discovery methods.”
“We are pleased to extend our work with AbCellera utilizing this company’s novel biologics technology,” said Steffen Nock, SVP & Global Head of Biologics at Teva. “This agreement will be complementary to our existing antibody discovery process with the potential to strengthen Teva’s capabilities in novel biologics discovery.”
Under the terms of the agreement, AbCellera will receive an upfront payment and research support, as well as milestone and royalty payments based on Teva’s development and commercialization of antibodies generated under this collaboration. Further terms of the agreement are not disclosed.
About AbCellera Biologics, Inc.
AbCellera is a privately held company that develops next-generation monoclonal antibody therapies and provides enabling technologies to biotechnology and pharmaceutical partners. AbCellera’s lead technology is a proprietary single-cell antibody discovery and immune profiling platform that allows for high-throughput screening of natural immune repertoires to rapidly identify lead therapeutic antibody candidates from any species, including humans.
Contact Kevin Heyries, PhD Telephone: 604.827.4151 Email: [email protected] Web: www.abcellera.com
